Membrane Protein-Based Vaccine Development Service
- Vaccine development for emerging viruses such as SARS-CoV-2 and RSV.
- Surface antigen screening for complex viruses like HIV and influenza.
- Tumor vaccine design targeting transmembrane receptor antigens.
- Construction and optimization of virus-like particles (VLPs).
- Antigen conformation studies and analysis of immune mechanisms.
Membrane Protein-Based Vaccine Development Service is a specialized solution focused on the screening and validation of membrane proteins as vaccine antigens, aiming to systematically explore their potential in rational vaccine design. By constructing physiologically relevant membrane protein-based vaccine candidates, this service provides robust scientific and technical support for novel vaccine development, particularly suited for targeting complex transmembrane or multi-pass membrane proteins.
Vaccines are biological preparations designed to stimulate the immune system to produce protective responses against specific pathogens and are commonly used to prevent infectious diseases. Traditional vaccines often rely on live attenuated or inactivated whole viruses, which may pose risks such as strong immune side effects or complex manufacturing processes. In recent years, innovative vaccine formats such as subunit vaccines and virus-like particle (VLP) vaccines have gained traction. Among them, membrane protein-based vaccines have emerged as promising candidates due to their high specificity and potential to target challenging membrane-associated antigens.
Singh B. et al. Critical Reviews in Microbiology. 2023.
Figure 1. Membrane architecture and outer membrane vesicles of Vibrio spp.
Membrane proteins are key structural components on the surface of pathogens that directly interact with host cells. They play essential roles in viral attachment, cell entry, and immune evasion. Due to their surface exposure, high conservation, and functional importance, membrane proteins are considered ideal antigen targets for eliciting neutralizing antibodies and protective immune responses. Membrane protein-based vaccine development focuses on accurately obtaining conformationally intact antigens of target membrane proteins and screening immunologically effective candidates using established evaluation methods. This strategy supports vaccine development against emerging viruses, cancer, and chronic infections.
MtoZ Biolabs offers Membrane Protein-Based Vaccine Development Service covering the entire workflow—from membrane protein expression, extraction, and structural validation to antigen screening and optimization. Our platform empowers the efficient development of advanced vaccine formats such as subunit vaccines and virus-like particle (VLP) vaccines.
Analysis Workflow
The general workflow of Membrane Protein-Based Vaccine Development Service is as follows:
1. Target Selection and Sequence Design
Identify membrane protein targets with immunogenic potential and optimize their expression sequences.
2. Expression System Construction
Select an appropriate heterologous system for efficient membrane protein expression.
3. Membrane Protein Extraction and Purification
Extract and purify conformationally stable membrane proteins under mild conditions.
4. Conformation Validation and Functional Assessment
Evaluate structural integrity and binding activity of the membrane proteins with receptors or antibodies.
5. Antigen Screening and Recommendation
Screen and recommend the most immunologically effective candidate antigens for downstream vaccine development.
Service Advantages
1. High Specificity Targeting Critical Pathogen Domains: Membrane proteins are often key antigens located on the surface of pathogens or tumor cells. They exhibit strong target specificity and immunogenic recognition, making them effective in eliciting robust and protective immune responses.
2. Conformation-Preserving Expression System: Utilizing optimized expression systems and gentle extraction/purification strategies, the native conformation of membrane proteins is effectively maintained. This minimizes immune response bias and enhances the accuracy of vaccine efficacy prediction.
3. Advanced Platform: MtoZ Biolabs established an advanced Membrane Protein-Based Vaccine Development Service platform, guaranteeing reliable, fast, and highly accurate service.
4. One-Time-Charge: Our pricing is transparent, no hidden fees or additional costs.
Applications
Application examples of Membrane Protein-Based Vaccine Development Service:
Related Services
Membrane and Membrane Protein Extraction Service
How to order?
